AI illustration · not actual product photoDetails from the source.
Source-listed Retatrutide (SKU RT100): 100mg*10vials. PriceList(1).pdf lists 343 per 10 vials but does not specify currency; the website displays $343 per 10 vials in USD per owner instruction. The source row does not establish the supplier-specific item's identity, lot quality, or approval.
- Catalogue code
- RT100
- Source specification
- 100mg*10vials
- Source document
- PriceList(1).pdf, page 4
- Photograph
- AI-generated illustration only — not an actual product photo or verified molecular depiction; owner-approved product photo still pending.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
The clinical molecule called retatrutide (development code LY3437943) is a single peptide engineered to activate three hormone receptors. It is a peptide scientifically, but the catalogue label alone does not verify that the supplier vial contains the clinical-trial molecule. The exact vial’s manufacturer, formulation, source, and quality are unverified.
Biological mechanism
The studied molecule activates the GIP, GLP-1, and glucagon receptors, pathways involved in glucose regulation, appetite, and energy balance. It is described in the clinical literature as a peptide conjugated to a fatty-diacid moiety. This mechanism describes the investigational molecule, not an analysis of the catalogue vial. [1] [3]
Research focus
Human research has investigated retatrutide in adults with obesity, including people with type 2 diabetes. A 2026 phase 3 obesity trial also assessed body weight, knee pain in a knee-osteoarthritis subgroup, and apnea events in an obstructive-sleep-apnea subgroup. [2] [3] [4]
Potential applications in the evidence
Only investigational settings are supported: body-weight outcomes in obesity, glycemic measures in type 2 diabetes, knee-pain outcomes in a knee-osteoarthritis subgroup, and apnea events in an obstructive-sleep-apnea subgroup. These study populations and outcomes are not established indications or proof of benefit from this catalogue item. [2] [3] [4]
Human evidence
Randomized human studies have reported changes in weight in obesity trials and in weight and glycemic measures in type 2 diabetes trials. In the 80-week phase 3 TRIUMPH-2 trial, mean weight changes across retatrutide groups were −11.9% to −18.8%, compared with −5.1% with placebo, and the publication reported improvements in glycemic control. In phase 3 TRIUMPH-1, body weight decreased relative to placebo, and reported knee-pain and apnea outcomes improved in the studied subgroups. These findings apply to defined investigational study material, selected participants, and clinical trial monitoring—not to the identity, effects, or safety of this catalogue vial. [2] [3] [4]
Known and potential effects
Gastrointestinal events, including nausea, diarrhea, vomiting, and constipation, were among the most frequently reported effects in trials. The phase 3 type 2 diabetes study also reported more hypotension and dysesthesia (abnormal sensations) with retatrutide than placebo. In the phase 2 obesity study, heart rate rose during treatment before declining later; one serious acute-pancreatitis event was reported. Trial findings do not define the complete risk profile. [1] [2] [4]
Safety and contraindications
No FDA-approved prescribing information for retatrutide establishes a contraindication list. The supplied documents do not verify this vial’s active ingredient, concentration, formulation, sterility, purity, storage history, or lot testing, so trial safety information cannot be transferred to it. FDA warns that unapproved versions of medicines do not undergo FDA review for safety, effectiveness, and quality before marketing. Product-specific safety and contraindications therefore cannot be confirmed. [5]
U.S. FDA / regulatory status
As of 2026-10-30, retatrutide remains investigational and is not an FDA-approved drug for any condition. FDA states that retatrutide is not an ingredient of an FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in compounding under federal law. This does not establish whether this exact catalogue vial is an approved drug, a compounded product, or material made for a research purpose. The PDF identifies no manufacturer, lot, formulation source, jurisdiction, or approval documentation, so its exact identity and approval status cannot be verified. Approval of any future active ingredient or branded formulation would not transfer to this supplier-specific vial. [5]
Evidence limitations
Early studies were limited in size and duration; larger and longer phase 3 trials add evidence but cannot establish rare or long-term risks or predict outcomes for all populations. The 2026 publications were funded by Eli Lilly, the molecule’s developer. None of the cited trials identifies or tests this supplier’s vial. Its composition, manufacturing controls, and regulatory status remain unverified. [1] [2] [3] [4] [5]
Supporting sources
- Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial New England Journal of Medicine · Peer-reviewed randomized phase 2 clinical trial. Supports: Peptide classification and receptor mechanism; phase 2 human findings and reported adverse effects.
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes The Lancet; indexed by PubMed, U.S. National Library of Medicine · Peer-reviewed randomized phase 2 clinical trial record and abstract. Supports: Human trial findings in type 2 diabetes, including glycemic and weight outcomes and gastrointestinal adverse events.
- Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity New England Journal of Medicine · Peer-reviewed randomized phase 3 clinical trial. Supports: 2026 phase 3 obesity findings and investigational knee-osteoarthritis and obstructive-sleep-apnea subgroup outcomes.
- Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial The Lancet · Peer-reviewed randomized phase 3 clinical trial. Supports: 2026 phase 3 weight and glycemic findings in obesity with type 2 diabetes, plus reported adverse events.
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss U.S. Food and Drug Administration · Official FDA safety and regulatory communication. Supports: FDA statement on retatrutide’s investigational status, no FDA-approved drug ingredient status, prohibition on compounding, and risks of unapproved products.